Neko Health, the innovative health assessment startup co-founded by Spotify’s Daniel Ek and Hjalmar Nilsonne, has successfully closed a Series C funding round, raising an impressive $700 million. This substantial investment was spearheaded by Lightspeed Venture Partners and O.G. Venture Partners, building on the company’s previous $260 million Series B round secured in January 2025. The capital infusion is set to accelerate Neko Health’s mission to revolutionize preventative health care through its cutting-edge technology.

At the core of Neko Health’s offering is its proprietary body-scanning technology, which is meticulously combined with traditional bloodwork to provide a holistic view of an individual’s health. The system now also incorporates detailed body composition information, catering to a broader range of health-conscious users. Hjalmar Nilsonne highlights the integration with Apple Health data, which empowers Neko Health’s medical clinicians with valuable real-world insights, enhancing the accuracy and personalization of their health assessments.

With existing operations in the U.K. and Sweden, Neko Health is poised for significant international expansion, with plans to open its inaugural U.S. location in New York. The company has already seen remarkable adoption, with over 100,000 individuals having undergone scans. Furthermore, more than 350,000 people have either joined the waitlist or scheduled appointments, indicating a strong market demand for its services. Notably, Calm founder Alex Tew publicly shared his positive experience, crediting a Neko Health scan with the early detection and removal of a malignant mole on his back, underscoring the potential life-saving impact of the technology.

The Series C round also saw participation from a diverse group of investors, including Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD. While Neko Health leads in this specialized field, it operates within an evolving landscape, with other tech-driven ventures like Midjourney exploring similar body-scanning concepts, albeit with different integration strategies such as spa experiences.

Key Takeaways

• Neko Health, co-founded by Daniel Ek, successfully raised $700 million in Series C funding from prominent investors.
• The company employs proprietary body-scanning technology, bloodwork, and Apple Health data integration for comprehensive health assessments.
• Neko Health is expanding globally, including an upcoming U.S. launch in New York, and has already served over 100,000 individuals.

Editor’s Analysis & Impact

This substantial funding round for Neko Health underscores a growing investor confidence in the preventative health technology sector. The company’s innovative approach, combining advanced body scanning with traditional diagnostics and personal health data, positions it as a potential disruptor in how individuals monitor and manage their well-being. The expansion into the U.S. market, particularly New York, signals aggressive growth ambitions and could significantly broaden access to proactive health insights. This trend suggests a future where personalized, data-driven health assessments become more mainstream, potentially shifting healthcare from reactive treatment to proactive prevention. However, challenges around data privacy, regulatory compliance, and ensuring equitable access to such advanced technologies will be critical considerations as the industry evolves.

Frequently Asked Questions

Q: What is Neko Health?
A: Neko Health is a health assessment startup co-founded by Spotify's Daniel Ek and Hjalmar Nilsonne, which uses proprietary body-scanning technology combined with bloodwork to provide comprehensive health insights.

Q: Who are the main investors in Neko Health's latest funding round?
A: The $700 million Series C funding round was led by Lightspeed Venture Partners and O.G. Venture Partners, with additional investments from firms like Atomico, General Catalyst, and Lakestar.

Q: Where is Neko Health planning to expand its services?
A: Neko Health currently operates in the U.K. and Sweden and is preparing to launch its first U.S. location in New York.